Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Elarekibep in Healthy Japanese Subjects
NCT05794672Phase 1Terminated
- Sponsor
- AstraZeneca
- Start
- Apr 2023
- Primary completion
- Jul 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of elarekibep in asthma (3 arms), sponsored by AstraZeneca. Primary endpoints: Incidence of Adverse events up to 67 days and Collection of blood samples for the measurement of safety immunobiomarkers. Started Apr 2023; status: terminated.
02
Drugs
elarekibep
03
Conditions
asthma
Beyond the preview
Go deeper on NCT05794672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05794672.